Universal treatment of multidrug-resistant TB is possible within current budgets with generic production

Generic production could make novel multidrug-resistant tuberculosis (MDR-TB) regimens available for US $53–507 per treatment course according to data presented at TB2016.

To read the full article, click here.


Source: HIV i-Base

To subscribe to the Weekly Newsletter of new posts, enter your email here:


News

By Polly Clayden

Published: Aug. 3, 2016, 1:03 p.m.

Last updated: Aug. 3, 2016, 1:08 p.m.

Print Share